» Articles » PMID: 31896942

Inter-laboratory Proficiency Testing Scheme for Tumour Next-generation Sequencing in Ontario: a Pilot Study

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2020 Jan 4
PMID 31896942
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A pilot inter-laboratory proficiency scheme for 5 Ontario clinical laboratories testing tumour samples for the Ontario-wide Cancer Targeted Nucleic Acid Evaluation (octane) study was undertaken to assess proficiency in the identification and reporting of next-generation sequencing (ngs) test results in solid tumour testing from archival formalin-fixed, paraffin-embedded (ffpe) tissue.

Methods: One laboratory served as the reference centre and provided samples to 4 participating laboratories. An analyte-based approach was applied: each participating laboratory received 10 ffpe tissue specimens profiled at the reference centre, with tumour site and histology provided. Laboratories performed testing per their standard ngs tumour test protocols. Items returned for assessment included genes and variants that would be typically reported in routine clinical testing and variant call format (vcf) files to allow for assessment of ngs technical quality.

Results: Two main aspects were assessed:■ Technical quality and accuracy of identification of exonic variants■ Site-specific reporting practicesTechnical assessment included evaluation of exonic variant identification, quality assessment of the vcf files to evaluate base calling, variant allele frequency, and depth of coverage for all exonic variants. Concordance at 100% was observed from all sites in the technical identification of 98 exonic variants across the 10 cases. Variability between laboratories in the choice of variants considered clinically reportable was significant. Of the 38 variants reported as clinically relevant by at least 1 site, only 3 variants were concordantly reported by all participating centres as clinically relevant.

Conclusions: Although excellent technical concordance for ngs tumour profiling was observed across participating institutions, differences in the reporting of clinically relevant variants were observed, highlighting reporting as a gap where consensus on the part of Ontario laboratories is needed.

Citing Articles

Inter-assay variability of next-generation sequencing-based gene panels.

Quy P, Fukuyama K, Kanai M, Kou T, Kondo T, Yoshioka M BMC Med Genomics. 2022; 15(1):86.

PMID: 35428255 PMC: 9013031. DOI: 10.1186/s12920-022-01230-y.


Precision cancer genome testing needs proficiency testing involving all stakeholders.

Maekawa M, Taniguchi T, Nishio K, Sakai K, Matsushita K, Nakatani K Sci Rep. 2022; 12(1):1494.

PMID: 35087199 PMC: 8795413. DOI: 10.1038/s41598-022-05589-x.


Multisite verification of the accuracy of a multi-gene next generation sequencing panel for detection of mutations and copy number alterations in solid tumours.

Bartlett J, Amemiya Y, Arts H, Bayani J, Eng B, Grafodatskaya D PLoS One. 2021; 16(10):e0258188.

PMID: 34597339 PMC: 8486135. DOI: 10.1371/journal.pone.0258188.

References
1.
Nagarajan R, Bartley A, Bridge J, Jennings L, Kamel-Reid S, Kim A . A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices. Arch Pathol Lab Med. 2017; 141(12):1679-1685. DOI: 10.5858/arpa.2016-0542-CP. View

2.
Jennings L, Arcila M, Corless C, Kamel-Reid S, Lubin I, Pfeifer J . Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017; 19(3):341-365. PMC: 6941185. DOI: 10.1016/j.jmoldx.2017.01.011. View

3.
Merker J, Devereaux K, Iafrate A, Kamel-Reid S, Kim A, Moncur J . Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. Arch Pathol Lab Med. 2018; 143(4):463-471. PMC: 6910717. DOI: 10.5858/arpa.2018-0336-CP. View

4.
Li M, Datto M, Duncavage E, Kulkarni S, Lindeman N, Roy S . Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2016; 19(1):4-23. PMC: 5707196. DOI: 10.1016/j.jmoldx.2016.10.002. View

5.
Sukhai M, Craddock K, Thomas M, Hansen A, Zhang T, Siu L . A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med. 2015; 18(2):128-36. DOI: 10.1038/gim.2015.47. View